Progress of Early Breast Cancer

Breast cancer is a major threat to women ‘ s health and early detection and treatment are essential. In recent years, there has been significant progress in the treatment of early breast cancer.In the area of local treatment, the routine application of the outpost lymphomy test has enabled many patients to avoid lymphomy and its complications. Several studies have explored the need for lymphocyte cleaning. For example, the ICARO study found that routine armpit lymphocytes clean-up is of little value for newly assisted cytocellular cell patients; SENOMAC tests show no difference in the non-recurrence rate of acceptance or non-acceptance of armpit lymphocyte clean-up for specific breast cancer patients. In addition, it is also possible to omit armpit surgery for eligible patients, such as 2 cm in diameter and an ultrasound examination of vaginal breast cancer in pre-operative armpits.Systematic treatment is an important component of early breast cancer treatment. For hormonal receptor-positive breast cancer, ovarian functional inhibition has become an important supplement to pre-menopausal high-risk patients, reducing the risk of relapse and all-caused mortality. At the same time, the introduction of cytological cytoprotein-dependent 4/6 inhibitors in endocrine treatment has shown good results in improving the survival and reoccurrence of non-invasive diseases. The use of immunosuppressants in combination with chemotherapy has some prospect of treating patients with high-risk estrogen-positive breast cancer, but the impact on their long-term survival needs to be further observed.The results of the treatment of triple-negative breast cancer vary. During the KEYNOTE-522 experiment, patients who had been subjected to a single form of Pablo received more significant benefits in terms of the non-incidental lifetime and the no-distant reoccurrence period; however, in the Alexandra/Impassion030 and NeoTRIP experiments, the non-incidental period of the patient who had not been significantly elevated was also protected by the addition of Adelijo. These results point to the need to further explore the factors that influence the effectiveness of treatment.There have also been new developments in the treatment of HeR2-positive breast cancer. KATHERINE studies show that the assisted drug Emerald Troteau is more beneficial to patients than tutole mono-resistant, which increases the survival rate of non-intrusive diseases and reduces the risk of death.In addition to treatment, survival care and assistive treatment care are also receiving attention. Obesity has a negative impact on the prognosis of breast cancer patients, and it is a useful attempt to help them develop healthy living habits, including through telephone interventions. In addition, with regard to the possibility of pregnancy following diagnosis of breast cancer, studies have found that temporary interruption of endocrine treatment for pregnancy does not significantly increase the risk of re-emergence in the short term, and that it is relatively safe for young breast cancer survivors who carry pathological mutations from BRCA1 and/or BRCA2.Treatment for early breast cancer is moving towards individualized, risk-adjusted treatment. Patients should be aware of these developments and actively cooperate with the treatment while maintaining a healthy lifestyle in order to improve its effectiveness and quality of life.References:[1] Yip Songqing, Wang Rue-chung, Huang Qin. Advances in Early Breast Cancer Care [J]. Chinese Journal of Outer Basic and Clinical Studies, 2024, 31(09): 1033-1037.